Trial reportFrontiers in immunology2018
Sinomenine Inhibits the Progression of Rheumatoid Arthritis by Regulating the Secretion of Inflammatory Cytokines and Monocyte/Macrophage Subsets.
Trial report in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 6 syntheses or guidelines pooled it, 235 citations in OpenAlex.
- Sinomenine ameliorates rheumatoid arthritis in rodent models: a systematic review and meta-analysis of anti-inflammatory and joint-protective effects.Frontiers in pharmacology · 2026Pooled it
- A Systematic Review on Natural Products, Nanotechnology and their Recent Updates Towards Management of CFA-induced Rheumatoid Arthritis.Current drug discovery technologies · 2026Pooled it
- Efficacy and safety of TCMs with anti-inflammatory effect in patients with rheumatoid arthritis: A network meta-analysis.Frontiers in immunology · 2023Pooled it
- Synovial Macrophages: Past Life, Current Situation, and Application in Inflammatory Arthritis.Frontiers in immunology · 2022Pooled it
- Association Between Rheumatoid Arthritis and Risk of Parkinson's Disease: A Meta-Analysis and Systematic Review.Frontiers in neurology · 2022Pooled it
- Methodological and reporting quality evaluation of meta-analyses on the Chinese herbal preparation Zheng Qing Feng Tong Ning for the treatment of rheumatoid arthritis.BMC complementary medicine and therapies · 2020Pooled it
- Ultrasound-Guided Zhengqing Fengtongning vs Corticosteroid Injections for Plantar Fasciitis: A Randomized Controlled Trial on Short- and Long-Term Efficacy.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- Sinomenine protects mice againstMicrobiology spectrum · 2026Article
- Phytochemicals in arthritis management: insight into pharmacodynamic potency with pharmacokinetic profile.Inflammopharmacology · 2026Review
- Corosolic acid alleviates rheumatoid arthritis by down regulation of the NF-κB/PI3K/AKT signaling pathway.Scientific reports · 2026Article
- Roles of immune cell metabolism in rheumatoid arthritis.Frontiers in immunology · 2026Review
- Traditional Chinese medicine and plant metabolites for rheumatoid arthritis via modulating gut microbiota: a scoping review evaluating the transition from correlation to causality.Frontiers in pharmacology · 2026Review
- Exploring the mechanism of action of tripterygium glycosides tablets in the treatment of rheumatoid arthritis based on the Lnc-ENST00000602558/IGF1 signaling pathway.Frontiers in pharmacology · 2026Article
- Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies.Frontiers in oncology · 2026Review
- Recent Advancement in Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.Current drug discovery technologies · 2026Review
- Natural compounds for the treatment of rheumatoid arthritis based on the 'gut‑joint axis' (Review).Molecular medicine reports · 2026Review
- Comprehensive overview of alternative medicine in the treatment of ankylosing spondylitis: Symptoms, pathogenesis, diagnosis and treatments (Review).Biomedical reports · 2026Review
- Heme oxygenase-1 activation in mononuclear phagocytes in acute Kawasaki disease.Frontiers in pediatrics · 2026Article
- The potential ofFuture science OA · 2025Article
- Effectiveness of Zhengqing Fengtongning in combination with routine rheumatoid arthritis treatment: A real-world multicenter retrospective study.Journal of traditional and complementary medicine · 2025Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory arthropathy associated with articular damage and attendant comorbidities. Even although RA treatment has advanced remarkably over the last decade, a significant proportion of patients still do not achieve sustained remission. The cause of RA is not yet known despite the many potential mechanisms proposed. It has been confirmed that RA is associated with dysregulated immune system and persistent inflammation. Therefore, management of inflammation is always the target of therapy. Sinomenine (SIN) is the prescription drug approved by the Chinese government for RA treatment. A previous study found that SIN was a robust anti-inflammation drug. In this study, we screened the different secretory cytokines using inflammation antibody arrays and qRT-PCR in both LPS-induced and SIN-treated RAW264.7 cells followed by evaluation of the ability of SIN to modulate cytokine secretion in a cell model, collagen-induced arthritis (CIA) mouse model, and RA patients. Several clinical indexes affecting the 28-joint disease activity score (DAS28) were determined before and after SIN treatment. Clinical indexes, inflammatory cytokine secretion, and DAS28 were compared among RA patients treated with either SIN or methotrexate (MTX). To explore the mechanism of SIN anti-inflammatory function, RA-associated monocyte/macrophage subsets were determined using flow cytometry in CIA mouse model and RA patients, both treated with SIN. The results demonstrated that SIN regulated IL-6, GM-CSF, IL-12 p40, IL-1α, TNF-α, IL-1β, KC (CXCL1), Eotaxin-2, IL-10, M-CSF, RANTES, and MCP-1 secretion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.